News | Vascular Access | January 31, 2017

Bard Recalls Halo One Thin-Walled Guiding Sheath Due to Sheath Separation, Kinking

Halo One Thin-Walled Guiding Sheath

The Halo One Thin-Walled Guiding Sheath.

January 31, 2017 — Bard Peripheral Vascular Inc. is recalling the Halo One Thin-Walled Guiding Sheath because the sheath body may separate from the sheath hub while removing the device from the patient's leg. The company also reports that the sheath may kink, and that its tip may become damaged during the procedure. The U.S, Food and Drug Administration (FDA) has identified this as a Class I recall, the most serious type of recall.  

Bard said the use of affected sheaths may result in prolonged procedure times and on additional surgical intervention to remove detached components from the patient. The affected product may cause other serious adverse health consequences such as internal tears and perforation to arteries or veins, excessive bleeding and death. The Halo One Thin-Walled Guiding Sheath is used to introduce and/or guide the placement of interventional and diagnostic devices into veins and arteries through an incision made on a patient's leg.

On Jan. 10, 2017, Bard sent a medical device recall notification, which instructed consignees to stop using, or further distributing, any affected products. It also requested checks all inventory locations for affected product codes and lot numbers and to remove any affected products from the shelves. 

If an affected product has been used, Bard asked users to complete and return the "Recall and Effectiveness Check Form," which was attached to the notification, and which indicates no product will be returned.

The effected lots of the Halo One Thin-Walled Guiding Sheath involved in the recall include product codes HAL545, HAL590 and HAL510F. Lot numbers include: 50137556, 50137557, 50137598 50137682 50137723, 50137735, 50137875, 50137965, 50138274, 50138119, 50138118, 50138122, 50138273, 50138435, 50138437, 50138701, 50138439, 50137570, 50137770, 50137979, 50138696, 50137866, 50137924, 50138170 and 50138765. The manufacturing dates include product made between April 12, 2016 to July 7, 2016. Distribution dates include: June 24, 2016 to July 12, 2016. 

The recall included 101 units distributed in Arizona, Florida, Kansas, Louisiana, Maine, Michigan, Missouri, Nevada, New Hampshire, New York, Ohio, Texas, Utah, and Washington.

For more information, contact the firm's recall coordinator at (800) 321-4254, Option #2, Ext. 2501 (Monday - Friday 6 a.m. to 3 p.m. Mountain Standard Time), or by e-mail at [email protected]

For more information from the FDA: www.fda.gov/MedicalDevices/Safety/ListofRecalls/ucm538821.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery

Related Content

Videos | Cath Lab | August 13, 2018
Jeffrey Schussler, M.D., FACC, FSCAI, FSCCT, FACP, interventional cardiologist at Baylor Scott White Heart and Vascul
Shockwave Launches Coronary Intravascular Lithotripsy in Europe
News | Cath Lab | May 30, 2018
Shockwave Medical recently announced the European commercial availability of Intravascular Lithotripsy (IVL) for...
FFR software on the GE Centricity CVIS. A trial from the 2018 EuroPCR meeting showed FFR improves long-term outcomes.
News | Cath Lab | May 29, 2018
May 29, 2018 — Ongoing controversy exists regarding the role of percutaneous coronary intervention (PCI) for stable c
SCAI Updates Consensus on Length of Stay for Percutaneous Coronary Intervention
News | Cath Lab | May 15, 2018
Revised guidelines incorporating new data on discharge criteria for patients undergoing elective percutaneous coronary...
No Benefit Found Using Sodium Bicarbonate, Acetylcysteine to Prevent Kidney Injury, the result of the PRESERVE Trial to prevent acute kidney injury (AKI), presented at SCAI 2018.  #SCAI, #SCAI2018,
Feature | Cath Lab | May 15, 2018
May 15, 2018 – The large-scale, international randomized PRESERVE clinical trial found high-risk patients for renal c
Angiogram of a STEMI patient.
News | Cath Lab | May 15, 2018
May 15, 2018 — A contemporary, real-world analysis shows lower mortality rates when culprit-only intervention is used
Recent Acquisitions Eroding Prices in Billion Dollar European Interventional Cardiology cath lab Market.
Feature | Cath Lab | May 07, 2018 | Simon Trinh and Jeffrey Wong
The European interventional cardiology market is currently valued at nearly $1.4 billion.
Videos | Cath Lab | May 07, 2018
Imran Ahmad, M.D., medical director of interventional cardiology, explains some of the new technologies his labs have
360 Photos | Cath Lab | April 20, 2018
A 360 degree view of the newest cath lab at Northwestern Medicine Central DuPage Hospital in Winfield, Ill., located
SCAI Announces Global Lecture Series for 2018 Scientific Sessions
News | Cath Lab | April 18, 2018
Many of the world’s leading interventional cardiologists and cardiovascular professionals will convene in San Diego,...
Overlay Init